Novo Nordisk posts Phase 3 icodec vs. glargine results; registers two observational studies

Novo Nordisk's week included one completed Phase 3 trial with results posted and two newly registered observational studies.

• A Phase 3 trial (NCT06340854) compared insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day, in participants with type 2 diabetes.¹ The study was marked completed with 412 participants enrolled¹ and its primary outcome was change in Glycated Haemoglobin (HbA1c) from Week 0 to Week 26.¹ Results were first posted 2026-07-02.
• A new observational survey (NCT07682363) is recruiting to study the attitudes, perceptions, and clinical practice in assessing liver fibrosis following a metabolic dysfunction-associated steatotic liver disease (MASLD) diagnosis, and the management of MASLD patients among Chinese physicians in the departments of endocrinology / hepatology / infection / gastroenterology in Grade IIIA hospitals in provincial capitals or municipalities.² It has an estimated enrollment of 470 participants.²
• A new population-based observational study in Korea (NCT07673822) is enrolling by invitation to measure how common cardiovascular, kidney, and metabolic diseases are in the Korean adult population and how often they occur together (overlap) over time (2013-2023).³ The study has an estimated enrollment of 800000 participants.³